Key features and details
- Rabbit polyclonal to AlaRS - C-terminal
- Suitable for: WB, IP
- Reacts with: Mouse, Human
- Isotype: IgG
Product nameAnti-AlaRS antibody - C-terminal
See all AlaRS primary antibodies
DescriptionRabbit polyclonal to AlaRS - C-terminal
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Rat, Rabbit, Horse, Cow, Chimpanzee, Cynomolgus monkey, Rhesus monkey, Gorilla, Chinese hamster, Orangutan
Synthetic peptide within Human AlaRS aa 918-968 (C terminal). The exact sequence is proprietary. (NP_001596.2).
Database link: P49588
- WB: HeLa, HEK-293T, Jurkat and NIH/3T3 whole cell lysates. IP: HeLa whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 6.8
Preservative: 0.09% Sodium azide
Constituents: 0.1% BSA, Tris buffered saline
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab226217 was affinity purified using an epitope specific to AlaRS immobilized on solid support.
Our Abpromise guarantee covers the use of ab226217 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 107 kDa.|
|IP||Use at 2-10 µg/mg of lysate.|
FunctionCatalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Also edits incorrectly charged tRNA(Ala) via its editing domain.
Involvement in diseaseCharcot-Marie-Tooth disease 2N
Sequence similaritiesBelongs to the class-II aminoacyl-tRNA synthetase family.
DomainConsists of three domains; the N-terminal catalytic domain, the editing domain and the C-terminal C-Ala domain. The editing domain removes incorrectly charged amino acids, while the C-Ala domain, along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs.
The C-terminal C-Ala domain (residues 756 to 968), along with tRNA(Ala), serves as a bridge to cooperatively bring together the editing and aminoacylation centers thus stimulating deacylation of misacylated tRNAs. The human domain can be used in vitro to replace the corresponding domain in E.coli.
- Information by UniProt
- AARS antibody
- AI316495 antibody
- Alanine tRNA ligase 1, cytoplasmic antibody
All lanes : Anti-AlaRS antibody - C-terminal (ab226217) at 0.04 µg/ml
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 50 µg
Lane 2 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 15 µg
Lane 3 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 50 µg
Lane 4 : Jurkat (human T cell leukemia cell line from peripheral blood) whole cell lysate at 50 µg
Lane 5 : NIH/3T3 (mouse embryo fibroblast cell line) whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 107 kDa
Exposure time: 3 minutes
AlaRS was immunoprecipitated from HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate (1 mg for IP, 20% of IP loaded) with ab226217 at 6 µg/mg lysate. Western blot was performed from the immunoprecipitate using ab226217 at 0.4 µg/ml.
Lane 1: ab226217 IP in HeLa whole cell lysate.
Lane 2: Control IgG IP in HeLa whole cell lysate.
Detection: Chemiluminescence with exposure time of 30 seconds
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab226217 has not yet been referenced specifically in any publications.